Thyroid Eye Disease

Viridian Therapeutics (VRDN) announced the pricing of its public offering of 11,425,000 shares at $22.00 each, potentially generating $251.35 million in gross proceeds. Underwriters have an option to purchase additional shares. Closing is expected around October 23, 2025. Viridian will use the funds to support commercialization of veligrotug and VRDN-003 for Thyroid Eye Disease, ongoing research and development, and general corporate purposes. Jefferies, Leerink Partners, Evercore ISI, and Stifel are managing the offering.